Latest News
DOB Equity, a Dutch family office and 49 per cent shareholder in ferry builder and operator Globology, has teamed up with Hooge Raedt Social Ventures (HRSV) to scale Globology’s fleet and increase the supply water transportation services around Lake Victoria in Kenya.
Globology builds and operates affordable, fast, and safe catamaran passenger ferries for the island communities on Lake Victoria.
With the initial support from DOB Equity, Globology has been able to design and build innovative water transportation from its jetty at Kisumu, Kenya, reaching over 500,000 passengers within two years of investment.
With the recent support from
BTIG has secured an investment from funds managed by Blackstone Tactical Opportunities, which the firm will leverage to expand its capabilities and accelerate growth.
Post investment, BTIG and its affiliates in Europe, Asia and Australia will continue to operate as fully independent entities. Financial terms of the private transaction have not been disclosed.
“Since we started 12 years ago, BTIG has been one of the fastest-growing institutional brokerage firms in the US. Partnering with Blackstone Tactical Opportunities will further enhance our offerings and allow us to advance key strategic initiatives,” says Scott Kovalik, co-founder and chief executive officer of
Solace Capital Partners, a private equity firm focused on distressed-for-control and special situations investments in North America, has closed its inaugural Solace Capital Special Situations Fund at USD576 million, in excess of its USD500 million target.
Solace has flexible capital and targets control-oriented investments in complex, distressed or capital-constrained, lower-middle market companies across numerous industries.
Typical investment size ranges from USD10 million to USD75 million.
To date, the fund has invested and committed more than USD120 million in five portfolio companies.
Solace’s managing partners Chris Brothers, Vince Cebula and Brett Wyard say: “We are pleased with the
O2 Investment Partners has appointed Sean Darin to the firm’s investment team.
Darin will be responsible for evaluating new transactions, due diligence, underwriting, and monitoring O2's portfolio companies.
Prior to joining O2, Darin worked for RIN Capital, a private investment firm, where he was responsible for evaluating and underwriting growth equity transactions, primarily in the healthcare space.
Prior to RIN Capital, Darin worked for FINNEA Group, a Detroit-based investment bank, where he specialised in executing middle market buy- and sell-side M&A transactions.
Darin began his career as an analyst in the financial institutions investment banking group of
HPS Investment Partners is to take a substantial minority investment in insurance broker NFP.
Upon the closing of the transaction, Madison Dearborn Partners (MDP), a private equity firm that took a control equity ownership position in NFP in 2013, will maintain a controlling stake in NFP, alongside NFP’s management and employees.
The transaction, which is subject to customary closing conditions, is expected to close in the first quarter of 2017. Terms were not disclosed.
“HPS’s investment in NFP is a further validation of the quality, performance and future opportunity of our business,” says NFP chairman and chief executive
Eze Software Group has rolled out a series of enhancements to its back-office operations workflows for private equity funds, simplifying a series of complex tasks to a single click.
Eze Investor Accounting (formerly known as Penny-It-Works) handles partnership and investor accounting for some of the largest hedge funds and their administrators.
It is now extending its reach into private equity by automating some PE-specific complex processes, such as waterfall schedules, with its v12.3 release.
“Institutional investors are demanding more concessions from private equity firms, thus making already complex waterfalls more elaborate. The new version of Eze Investor Accounting enhances
Exit Strategies, a specialist in the buy side, mergers and acquisitions space, closed three new buy side transactions in September 2016.
“Our proprietary process and tools continue to be validated by these high quality transactions,” says Jordan Wagner, co-founder at Exit Strategies.
The September closed deals originated and facilitated by Exit Strategies on the buy side included Align Capital Partners, a private equity firm with USD325 million in their current fund, which acquired Alliance Source Testing, an Alabama-based company focused on providing accurate and consistent source testing solutions.
Alpine Investors, a San Francisco-based private equity firm with USD900
Healthcare-focused private equity firms DW Healthcare Partners (DWHP) and Linden Capital Partners are to acquire Edge Systems.
Headquartered in Signal Hill, California, Edge is a manufacturer and marketer of non-invasive equipment and consumables used in aesthetic skin health treatments.
Edge's leading product is the HydraFacial line of facial skin rejuvenation devices, which provide a non-invasive, multistep treatment in one sitting that delivers results without downtime or irritation. Edge has a current installed base of over 7,000 systems placed with dermatologists, plastic surgeons, and medical spas across 75 countries.
As part of an aesthetics sector effort, Linden and DWHP
Advent International is to acquire a majority ownership interest in V.Group, a marine and offshore vessel management and support services provider, from Omers Private Equity (OPE).
OPE will reinvest in V.Group, working with Advent and the management team to support the continued growth and development of the business.
V.Group’s management team will retain a minority stake in the company.
The value of the transaction has not been disclosed.
V.Group specialises in the technical management of maritime assets outsourced by ship owners, and the provision of a wide-range of high-value technical, personnel and advisory services. Operating out of
A cross-border team from law firm Goodwin represented the neuroscience company Cerevance in its financing by Lightstone Ventures and Takeda Pharmaceutical.
Cerevance will focus on discovering and developing novel therapeutics for neurological and psychiatric disorders.
The USD36 million funding round includes a USD21.5 million Series A financing investment from Takeda and Lightstone Ventures, with each joining Cerevance’s board of directors.
Cerevance will have sites in both Massachusetts and the UK. Takeda has provided a 25-person neuroscience research team from its Cambridge, UK site, including industry veterans, fully equipped laboratory space, and licenses to a portfolio of preclinical and clinical
Special Reports
Featured
Events
12 November, 2026 – 8:00 am
12 November, 2026 – 5:00 pm
